A scientific agreement between MDxHealth and QUT bluebox, the Queensland University of Technology's commercialization arm, will evaluate and develop a liquid biopsy epigenetic assay for early oral cancer detection. Under the deal, the first licensing option for commercial diagnostic rights will go to MDxHealth; proceeds will be used for research and translational activities at the university and MDxHealth's urologic cancer diagnostics research and development pipeline.
MDxHealth, QUT bluebox enter scientific deal on oral cancer test
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.